A Study of RO4917523 in Patients With Fragile X Syndrome

NCT01517698 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

Fragile X Syndrome

Interventions

DRUG: Placebo
DRUG: RO4917523 0.5 mg
DRUG: RO4917523 1.5 mg

Sponsor

Hoffmann-La Roche